NCT02912936

A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease

A Medium Chain Triglyceride INTervention for Alzheimer Disease (A MINT for AD)

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: University of British Columbia · Academic / Other
• Sex: All
• Age: 50 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine safety, tolerability, and pharmacokinetics/dynamics of a ketogenic dietary supplement containing medium chain triglycerides (MCTs) in patients with Alzheimer disease (AD). Novel imaging and laboratory biomarkers in response to this intervention will also be explored.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Ketogenic medium chain triglyceride drink (MCT drink)	10 days supplementation with the MCT drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
DIETARY_SUPPLEMENT	Placebo	10 days supplementation with the placebo drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.

Timeline

• Start date: 2016-09-01
• Primary completion: 2019-12-01
• Completion: 2019-12-01
• First posted: 2016-09-23
• Last updated: 2018-12-05

Locations

1 site across 1 country: Canada